Arena Pharmaceuticals Issued Patent for 5-HT2A Receptor Modulators by European Patent Office
APD125, Arena's Drug Candidate for the Treatment of Insomnia, Covered Under Patent
Arena Pharmaceuticals, Inc. announced that it was granted patent number 1558582, entitled "Diaryl and Arylheteroaryl Urea Derivatives as Modulators of the 5-HT2A serotonin Receptor Useful for the Prophylaxis and Treatment of Disorders Related Thereto," by the European Patent Office. The patent relates to a class of inverse agonists to the 5-HT2A serotonin receptor, which is thought to be involved in the regulation of sleep architecture and sleep maintenance. These inverse agonists may be useful in pharmaceutical compositions for the treatment of insomnia. APD125, discovered by Arena, is an orally available 5-HT2A receptor modulator covered under the patent. Arena intends to validate the patent in 31 European jurisdictions, including Germany, France, Italy, the United Kingdom and Spain.
Other news from the department research and development
